I'm LongbridgeAI, I can summarize articles.Ryan Langston, an analyst from TD Cowen, has reiterated a Hold rating on Enhabit, Inc. with a price target of $13.80, citing factors related to the company's pending acquisition and recent financial results. Despite first-quarter revenue meeting expectations, profitability fell short due to higher service costs. With an all-cash buyout expected to close soon, Langston believes the stock is fairly valued at the transaction price. Truist Financial also maintains a Hold rating with the same price target.
Ryan Langston, an analyst from TD Cowen, maintained the Hold rating on Enhabit, Inc. The associated price target remains the same with $13.80.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ryan Langston has given his Hold rating due to a combination of factors tied primarily to Enhabit’s pending acquisition and recent results. He notes that while first-quarter revenue was roughly in line with expectations, profitability lagged as adjusted EBITDA came in below both his estimate and the Street’s, with higher-than-anticipated service and administrative costs pressuring margins.
Despite modest growth in both the home health and hospice segments, operational metrics such as rising cost per visit and mixed volume trends limit near-term upside. With an all-cash buyout at $13.80 per share expected to close shortly and the company no longer providing guidance, he views the stock as fairly valued at the transaction price and thus keeps a Hold recommendation, leaving his $13.80 price target unchanged.
According to TipRanks, Langston is an analyst with an average return of -4.3% and a 37.12% success rate. Langston covers the Healthcare sector, focusing on stocks such as Astrana Health, Addus Homecare, and HCA Healthcare.
In another report released on May 8, Truist Financial also maintained a Hold rating on the stock with a $13.80 price target.